Galapagos NV announced that it has entered into a strategic collaboration agreement with Thermo Fisher Scientific Inc. for the decentralized manufacturing of Galapagos' point-of-care CAR-T product candidate in the San Francisco area. Under the terms of the agreement, Thermo Fisher will provide GMP manufacturing as well as BioServices and Specialty Logistics for Galapagos' CAR-T hemato-oncology clinical program in the San Francisco area, effective January 2024. Galapagos will initiate the technology transfer to enable Thermo Fisher's manufacturing activities.

This collaboration follows Galapagos' agreement with Landmark Bio for decentralized CAR-T manufacturing in the Boston area announced in November 2023.